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Immunotherapy is a promising treatment option for non–small-cell lung cancer patients. Immunotherapy clinical 
trials include for example PD-(L)1 and CTLA4 blockers, but 
also activating interleukins (IL). The related adverse events are 
different from that of chemotherapy-based treatment and new 
lesions can be the result of so called pseudo-progression instead 
of real tumor progression.1,2 Differentiation among progressive 
disease, pseudo-progression, and infectious disease can be 
challenging, as was the case for the patient described below.
This patient was diagnosed with metastasized non–
small-cell lung cancer (adenocarcinoma). At diagnosis, mag-
netic resonance imaging (MRI) of the brain was normal. 
First-line treatment consisted of four cycles of chemotherapy 
(gemcitabin/cisplatin) resulting in a partial response. As a 
maintenance treatment, she was treated with the immuncyto-
kine Selectikine (modiﬁed IL-2 [NHS-IL2]) in a phase I trial 
(NCT00879866).3 After 2 months, she presented with nausea, 
vomiting, and an altered mental status. Brain MRI showed 
extensive supra- and infratentoral perivascular enhancement, 
with additional leptomeningeal enhancement at the brainstem 
and pineal gland (Fig. 1). Extracranially, new liver metastases 
were found. Differential diagnosis of the brain lesions consisted 
of brain metastases, an (opportunistic) infection or polyoma 
JC virus causing progressive multifocal leukoencephalopathy 
(PML) as part of an immune reconstitution syndrome (IRIS) 
due to the immunotherapy, and pseudoprogression. Serum 
viral serology and cerebrospinal fluid cultures for polyoma JC, 
HIV, toxoplasma, CMV, HSC, VZV, mycobacteria, cryptococ-
cus, and yeasts were negative. Cerebrospinal fluid cytology 
showed malignant cells. After 3 weeks she died; brain obduc-
tion showed extensive adenocarcinoma metastases (Fig. 2). 
Additional staining did not show an intracranial immune 
response (no influx of B-cells, T-cells, or macrophages).
In this patient, MRI ﬁndings were not equivocal. 
Brain metastases are located mostly at the border of gray 
and white matter and extensive perivascular enhancement 
is not a  typical ﬁnding for brain metastases although some 
cases are described.4,5 Brain MRI ﬁndings in PML-IRIS are 
consistent with the ﬁndings in our patient. Typical PML lesions 
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FIGURE 1. Brain MRI. Transverse T2-weighted images 
(A) and transverse (B) and coronal (C) contrast enhanced 
T1-weighted images show numerous punctiform hyperin-
tense lesions at T2-weighted imaging, with enhancement 
after administration of gadolinium. The lesions follow a more 
or less curved pattern, consistent with perivascular distribu-
tion, without lesions at the gray-white matter interface.
FIGURE 2. Brain autopsy. A and B, Macroscopic aspect of 
brain tissue show multiple millimetric nodules located along 
the perivascular spaces; (C) microscopy shows moderately 
differentiated tubuli with mucin-forming cilindric cells, consis-
tent with adenocarcinoma metastases.
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are diffuse, with variable size and shape, mainly subcortical 
located and hyperintensive in T2-weighted images. They are 
found almost exclusively in the white matter with sparing of 
the periventricular white matter.6 Contrast enhancement can be 
seen in PML-IRIS due to local inflammation and breakdown of 
the blood–brain barrier.6 PML-IRIS has been increasingly diag-
nosed in patients treated with immunomodulation when T-cell 
function is restored after removal of immunosuppression.7
In conclusion, miliary brain metastases are rare 
and remain a diagnostic challenge especially in the era of 
immunomodulation.
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